All In Biotech

Drug Trial Radar · NCT03582176

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Apr 26, 2019

Primary completion

Sep 29, 2024

Study completion Dec 17, 2024

Sponsor

Lead sponsor
University of CalgaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
Jul 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.

Conditions

  • Elbow Fracture
  • Elbow Injury
  • Elbow Dislocation

Interventions

  • Lactose PlaceboDrug

    One capsule by mouth twice per day

  • Ketotifen Fumarate 2mgDrug

    2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

  • Ketotifen Fumarate 5mgDrug

    5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Elbow Extension-Flexion Arc of MotionTime frame: 12 weeks post-randomization

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Maryland Medical Centre

    Baltimore, Maryland

  • Carolinas Medical Center

    Charlotte, North Carolina

  • University of Vermont Medical Center

    Burlington, Vermont

  • Peter Lougheed Centre

    Calgary, Alberta, Canada

  • Foothills Medical Centre

    Calgary, Alberta, Canada

  • South Health Campus

    Calgary, Alberta, Canada

  • Sturgeon Community Hospital

    St. Albert, Alberta, Canada

  • Royal Columbia Hospital

    New Westminster, British Columbia, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • St. Joseph's Health Care London

    London, Ontario, Canada

  • The Ottawa General Hospital

    Ottawa, Ontario, Canada

  • The Ottawa Civic Hospital

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.